“Biomarkers are foundational to how we understand and treat disease, yet the way we measure them remains constrained by legacy approaches. ViewsML is redefining how biomarkers are measured and analyzed – unlocking a step-change in speed, scale, and accessibility across research and clinical settings,” said Zeeshan Ali, Partner, Wittington Ventures. “Virtual staining has the potential to accelerate workflows, lower costs, and unlock new applications across translational research, diagnostics, clinical trials and emerging areas such as neurodegenerative disease – driving faster insights and improved patient outcomes.”